2. A composition comprising a compound according to claim 1, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

3. The composition according to claim 2, in combination with an additional therapeutic agent.

4. The composition according to claim 3, wherein the additional therapeutic agent is a chemotherapeutic agent.

5. Use of a compound according to claim 1 in the manufacture of a medicament for treating a disorder, wherein the disorder is an autoimmune disease, a heteroimmune disease, an inflammatory disease, a cancer, a disease of the bone and joints, or a thromboembolic disorder.

6. The use according to claim 5, wherein the disorder is selected from rheumatoid arthritis, multiple sclerosis, diabetes, B-cell chronic lymphocytic leukemia, acute lymphocytic leukemia, hairy cell leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, colorectal cancer, pancreatic cancer, bone cancer, bone metastasis, osteoporosis, diabetes, irritable bowel syndrome, Crohn's disease, systemic lupus erythematosis, or disorders associated with renal transplant.

7. Use of a compound according to claim 1 in the manufacture of a medicament for treating a disorder selected from a proliferative disorder, a hyperproliferative disease, an immunological-mediated diseases, a disease of the respiratory tract, a skin disorder, a gastrointestinal disorder, a systeminc disease, or allograft rejection.

8. Use of a compound according to claim 1 in the manufacture of a medicament for treating a disorder, wherein the disorder is a carcinoma selected from breast cancer, glioblastoma, lung cancer, cancer of the head and neck, colorectal cancer, bladder cancer, non-small cell lung cancer, squamous cell carcinoma, salivary gland carcinoma, ovarian carcinoma, colorectal cancer, or pancreatic cancer.

9. Use of a compound according to claim 1 in the manufacture of a medicament for treating neurofibromatosis type I (NF1), neurofibromatosis type II (NF2) Schwann cell neoplasms (e.g. MPNST's), or a Schwannoma.

10. Use of a compound according to claim 1 in the manufacture of a medicament for treating a disorder in a patient selected from a neurodegenerative disorder, or a solid or hematologic malignancy.